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ABSTRACT
Glioblastoma remains among the most aggressive of all human and canine 
malignancies, displaying high mortality rates and limited treatment options. We 
propose that given the similarities between canine and human gliomas, such as 
incidence of occurrence, histopathology, molecular characteristics, and response to 
therapy, that canine gliomas are a natural model of the human disease. A range of 
human and canine tumours have been shown to harbor specific subpopulations of cells 
with stem cell-like properties that initiate and maintain neoplasticity while resisting 
conventional therapies. Here, we show that both canine and human glioma cell lines 
contain a small population of cancer stem cells (CSCs), and by molecular profiling 
highlight the important role of the epidermal growth factor receptor (EGFR) pathway 
in canine CSCs. EGFR signaling is crucial in the regulation of cancer cell proliferation, 
migration and survival. To date EGFR-targeted interventions alone have been largely 
ineffective. Our findings confirm that specifically inhibiting EGFR signaling alone has 
no significant effect on the viability of CSCs. However inhibition of EGFR did enhance 
the chemo- and radio-sensitivity of both canine and human glioma CSCs, enabling this 
resistant, tumourigenic population of cells to be effectively targeted by conventional 
therapies.
INTRODUCTION
Malignant gliomas are an aggressive form of brain 
cancer, in both humans and dogs, with a poor prognosis 
despite surgery, chemotherapy and ionising radiation [1-3]. 
In humans, the median survival time after diagnosis of 
glioblastoma multiforme (GBM), the most common form 
of malignant glioma, is 15 months [4]. There is a clear 
need for more effective strategies for the treatment of 
GBM, but many drug trials fail because the pre-clinical 
animal models do not sufficiently represent the human 
disease [5, 6]. The size and structure of the dog’s brain, 
histopathology and molecular characteristics of canine 
GBM, as well as the presence of the intact immune system, 
all support canine brain tumours as naturally occurring 
models of human glioma [5, 7]. This comparative 
approach may yield translational advancement for novel 
diagnostic, drug and therapeutic studies.
In both human and veterinary medicine radiotherapy 
is a key treatment modality for brain tumours, but the 
efficacy is limited by radioresistance [8]. Recently, it has 
been established that in many types of cancer the bulk 
of the cells that make up the tumour are derived from a 
small population of cancer stem cells (CSCs) [9]. Glioma 
CSCs share characteristics with normal stem cells such 
as expression of neural stem cell markers, properties of 
self-renewal, extensive proliferation, and the ability to 
differentiate into more mature neural lineages. These cells 
have also been assigned a role in tumour angiogenesis and 
treatment resistance, and upon intercranial transplantation 
onto immunocompromised mice can successfully seed 
new tumours [10-15]. Thus, CSCs are likely to be 
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responsible for initiation, progression and relapse of 
malignant gliomas, as conventional therapies that target 
the bulk of the tumour will fail to cure the disease because 
the CSCs will be unaffected and are able to recapitulate 
the tumour. Therefore it is imperative to target CSCs in the 
treatment of this disease.
There are genetic aberrations associated with 
GBM; amplification of epidermal growth factor receptor 
(EGFR) is a frequent finding that has been described in 
40-50% of all human glioblastomas [16-18]. EGFR is a 
tyrosine kinase that is activated by ligand binding, thereby 
inducing receptor dimerization and auto-phosphorylation 
of key tyrosine residues. EGFR signaling affects many 
cellular events including cell survival, proliferation, 
differentiation, metabolism, and migration [7, 19]. In 
response to irradiation, EGFR promotes intracellular 
downstream signaling involving, among others, mitogen-
activated protein kinase (MAPK) and phosphatidylinositol 
3-kinase (PI3K), these pathways mediate cell survival and 
radio-resistance [20, 21]. EGFR also directly interacts with 
and enhances the activity of DNA-PK. DNA-PK plays a 
central role in non-homologous end joining double strand 
break repair [22, 23]. Activation of EGFR thereby exerts 
a protective function against DNA damage and promotes 
tumour cell survival.
In this study, we isolated and characterised CSCs 
from a canine and a human glioma cell line and showed 
that these cells express stem cell markers; are more 
invasive; more tumourigenic and more resistant to the 
cytotoxic effects of chemotherapy and ionising radiation, 
in comparison to their non-stem cell counterparts. Global 
transcriptional analysis of these CSCs revealed that they 
have a distinct gene expression profile consisting of over 
10,000 significant differences, compared to non-CSCs. 
Moreover, a number of the most upregulated genes in 
CSCs are activators of EGFR. Concurrently we showed 
that CSCs have enhanced basal activation of the EGFR 
pathway that can be inhibited by the EGFR tyrosine 
kinase inhibitor, gefitinib. Our findings demonstrated 
that gefitinib treatment enhanced radio-sensitivity of both 
canine and human glioma CSCs, enabling this resistant, 
tumourigenic population of cells to be effectively targeted 
by ionising radiation. This data further validates canine 
glioma as a model for the human disease supporting the 
development of new therapeutic strategies in both human 
and veterinary medicine.
RESULTS
Glioma stem cells express stem cell markers, 
increased invasiveness and increased 
tumourigenicity
In this study we have utilised an established serum-
free cell culture system that favours the proliferation of 
undifferentiated cells thereby enriching for CSCs, which 
grow as spheres [13]. Expression of the stem cell marker 
CD133 was characterised by magnetic cell sorting [13]. 
Cells from the canine glioma cell line J3T and the human 
glioma cell line LN18 contain a small subpopulation of 
CD133+ cells (1.17 ±0.58 % (n = 8) and 2.07 ±0.43 % 
(n = 4), respectively), that are significantly better at 
forming spheres (Figure 1A and 1B), and express higher 
levels of the embryonic stem cells markers Oct4, Nanog 
and STAT3 (Figure 1C) than CD133- cells (similar results 
were obtained for LN18 CSC, data not shown).
The metastatic potential of CSCs, which is the ability 
of a CSC to migrate from the tumour microenvironment 
and subsequently invade and attach at a secondary site, is 
proposed to be mediated by the epithelial-to-mesenchymal 
transition (EMT) [24, 25]. Here we show that J3T spheres 
have a mesenchymal phenotype, whereby expression of 
E-Cadherin and β-catenin was significantly decreased, and 
that of Fibronectin was significantly increased compared 
to adherent cells (Figure 1D), and that CSCs are much 
more invasive in vitro (Figure 1E and 1F) (similar results 
were obtained for LN18 CSC, data not shown). To 
determine if spheres were more likely to form tumours in 
vivo than adherent cells, we utilised the chicken embryo 
chorioallantoic membrane (CAM) model: the CAMs of 
day 7 chicks were inoculated with either fluorescently 
labelled dissociated spheres or adherent cells. At day 10 of 
development 3-dimensional tumours were visible in 100% 
of membranes inoculated with dissociated spheres but not 
adherent cells. These micro-tumours were visualized under 
the fluorescence microscope; sphere cells were brightly 
fluorescent and had radiated out from the 3-dimensional 
tumour growths, invading the surrounding blood vessels 
of the CAM. In contrast, adherent cells were localised to 
the initial site of inoculation (Figure 1G). Therefore CSCs 
have a greater in vivo tumourigenic capacity than non-
CSCs cells.
CSCs exhibit greater resistance to radiation-
induced cytotoxicity
To determine whether spheres cells preferentially 
survive after treatment with external beam radiation, 
spheres derived from J3T and LN18 cell lines, were 
disassociated into single cells and treated with increasing 
doses of ionising radiation. Clonogenic survival was 
determined: J3T and LN18 spheres demonstrated a 
significantly increased resistance to radiation-induced 
replicative cell death compared to non-CSC adherent 
cells (Figure 2A and 2E, respectively). Similar results 
were obtained when CSCs were isolated by expression of 
CD133 (Figure 2B and 2F, respectively). Cell viability was 
assayed 48 hours after treatment: J3T non-CSCs showed 
a dose-dependent decrease in cell viability whereas CSCs 
were inherently resistant to the cytotoxic effect of radiation 
(Figure 2C and 2D), and therefore in a physiological 
setting may contribute to tumour repopulation.
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Figure 1: Isolation and characterisation of glioma cancer stem cells (CSCs). A small population of CD133+ cells exists in 
canine glioma J3T cell line (A) and the human glioma LN18 cell line (B) and readily form spheres compared to CD133- cells. Data are 
representative of three independent experiments ±SD (*p < 0.001). Images were taken at 40x magnification. (C) Reverse transcriptase 
(RT)-PCR analysis of embryonic stem cell markers: Nanog, Oct4, STAT3, and β-actin gene expression levels of J3T CD133+ and CD133- 
cells. (D) Western blots analysis of cell lysates derived from J3T adherent cells and spheres for markers of EMT: E-cadherin, Fibronectin, 
β-catenin, with β-actin as a loading control. 30 μg was loaded per lane (E) J3T CSCs show an increased invasive potential in vitro. Invasive 
ability of J3T adherent cells and spheres was analysed using a collagen based invasion assay. (F) Invading cells were quantified by 
measuring the optical density at 560 nm (** p < 0.005). (G) Glioma CSCs are enriched for higher tumourigenicity in vivo. Disassociated 
J3T spheres and adherent cells were inoculated directly onto the chorioallantoic membrane of a chicken embryo at day 7 of development. 
All cells were fluorescently labelled and imaged 3 days after inoculation.
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Treatment of CSCs with doxorubicin increases 
the size of the CSC population and highlights 
defects in activation of p53
Similarly, J3T CD133+ cells were resistant to the 
cytotoxic effect of the chemotherapy drug, doxorubicin. 
Doxorubicin is an anti-tumour antibiotic DNA damaging 
agent and is commonly used in veterinary and human cancer 
chemotherapy protocols. Here, CD133+ and CD133- cells 
were treated with increasing concentrations of doxorubicin 
and cell viability was assayed 48 hours after treatment. 
CD133+ cells demonstrated significantly increased resistance 
to doxorubicin induced cell death compared to CD133- cells 
(Figure 3A). Doxorubicin treatment also increased the size of 
the CD133+ population in a dose dependent manner (Figure 
3B), further supporting the finding that CSCs are resistant to 
doxorubicin treatment. To determine if resistance of CSCs to 
DNA damaging agents was due to defects in the p53 pathway, 
we treated CD133 sorted cells with doxorubicin and by 
western blotting analysed protein expression of key members 
of the pathway. In response to doxorubicin, CD133- cells 
showed a transient increase in p53 levels and phosphorylation 
of p53 serine-15, an ATM target that is associated with 
activation of p53 transcriptional activity [26], and of the 
p53 transcriptional target MDM2 at 4 hours post-treatment 
(Figure 3C). Levels of γH2AX, an ATM target and a marker 
of DNA double strand breaks [27], similarly increased 4 hours 
post-treatment in CD133- cells (Figure 3C), whereas, in 
CD133+ cells induction of γH2AX, p53, phosphorylation 
of p53 serine-15, and induction of MDM2 was markedly 
reduced (Figure 3C). The primary role of p53 is as a stress-
activated transcription factor therefore reduced p53 activity 
in CSCs may be linked to p53 protein localization [28]. In 
untreated non-CSC adherent cells, p53 protein was detected 
at a low level and was located in the cytosolic and nuclear 
fractions, whereas in untreated CSCs p53 protein levels 
were relatively low and associated with the nuclear fractions 
(Figure 3D). Upon DNA damage, the p53 protein levels in 
adherent cells increased in both the nuclear fractions, whereas 
in CSCs p53 protein levels and subcellular localisation 
remain unchanged (Figure 3D). Similarly, phosphorylation 
of p53 at serine-15 was undetectable in untreated adherent 
and sphere cells, but upon DNA damage a high level of 
phosphorylation of p53 at serine-15 in the nuclear fractions 
of adherent cells was detectable, whereas there was a low 
level of phosphorylation of p53 at serine-15 detected in CSCs 
(Figure 3D). The total protein content of each fraction was 
evaluated qualitatively by coomassie staining (Figure 3D).
Global analysis of gene expression reveals 
significant differences in the molecular profiles of 
CSCs and non-CSCs
We performed gene expression profiling of J3T 
CSCs and non-CSCs, minus (0 Gy) or plus (5 Gy) 
external beam radiation, using the Affymetrix 
GeneChip® Canine 2.0 Array. Untreated CSCs, 
represented by sphere cells, differentially expressed (i.e. 
up- or down regulated >2-fold with a false discovery rate 
(FDR) of 0.05) 15,193 genes compared to non-CSCs. To 
obtain a manageable number of gene differences, the 
FDR was decreased to 0.005. Under these parameters, 
10,358 genes were differentially expressed in CSCs 
compared to non-CSCs. A similar number of gene 
expression changes were observed between CSCs 
and non-CSCs post-irradiation treatment (Table 1). 
Interestingly, radiation induced more mRNA changes 
in non-CSCs (265) compared to CSCs (45). Principle 
component analysis shows a distinct separation of CSC 
and non-CSC populations (Figure 4A) and the heatmap 
shows that non-irradiated and irradiated CSCs cluster 
more closely than with non-irradiated and irradiated non-
CSCs (Figure 4B). Further pathway analysis showed that 
the differential expression profile of non-irradiated CSCs 
encompassed genes involved in a variety of biological 
processes and diseases including cell cycle regulation, 
protein synthesis, cell growth, proliferation, DNA repair, 
apoptosis, and cancer (Figure 4C). Significantly, genetic 
disorder and cancer were the top diseases identified in 
the analysis (Table 2), indicating that gene expression 
profiles associated with cancer are more prevalent in 
the CSC population than the non-CSCs. The top ten 
upregulated genes in CSCs compared to non-CSCs are 
shown in Table 3. Similar results were obtained for 
irradiated CSCs compared to irradiated non-CSCs (data 
not shown). Validation of the microarray was carried out 
by qRT-PCR (Figure 4D).
EGFR is constitutively active in CSCs
Activators of the EGFR pathway, including EDNRA, 
CXCR7, IGFBP2 and EGR1, dominated the top 10 
upregulated genes in CSCs compared to non-CSCs, as 
identified by microarray analysis. Although elevation of 
EGFR gene expression was not detected, CSCs do exhibit 
a higher basal level of EGFR protein that is constitutively 
phosphorylated at serine-1047 and tyrosine-1173. 
Constitutive phosphorylation of AKT, a downstream target 
of EGFR, indicates that the EGFR pathway is constitutively 
active in CSCs in contrast to non-CSCs (Figure 5A). To 
determine the effect of EGFR inhibition J3T adherent cells 
and spheres were treated with gefitinib, a selective inhibitor 
of the tyrosine kinase site in the catalytic domain of EGFR. 
In CSCs, gefitinib inhibited phosphorylation of EGFR at 
serine-1047 and tyrosine-1173, and inhibited activation of 
AKT. The total levels of EGFR and AKT were unaffected 
until 6 hours post-treatment where there is a decrease in 
EGFR levels in both cell populations. Non-CSCs showed 
no basal activation of the either the EGFR or AKT pathway 
(Figure 5A).
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Figure 2: CSCs are resistant to radiation treatment. Analysis of colony forming ability was assayed after J3T adherent cells and 
spheres (A), and CD133 sorted cells (B) were treated with increasing doses of ionising radiation. Cell viability of J3T adherent and spheres 
(C) and CD133 sorted cells (D) was assayed 48 hours after treatment. Analysis of colony forming ability was assayed after LN18 adherent 
cells and spheres (E), and CD133 sorted cells (F) were treated with increasing dose of ionising radiation. (* p < 0.005).
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Figure 3: Doxorubicin treatment enriches CSCs subpopulation and highlights that in CSCs p53 activity is attenuated 
and aberrantly localised within the cell. (A) Cell viability of MACS-sorted J3T CD133+ and CD133- cells was assayed 48 hours 
after treatment with increasing doses of doxorubicin (* p < 0.005). (B) J3T cells were treated with the indicated doses of doxorubicin and 
the percentage CD133+ cells was determined 24 hours post-treatment. (C) CD133+ and CD133- cells were treated with doxorubicin and 
harvested 4 hours after treatment. Cell lysates were probed for the expression of phosphorylation of p53 at serine-15, MDM2, γH2AX and 
β-actin as a loading control. 30 μg was loaded per lane. (D) The subcellular localisation of p53, in J3T adherent cells and spheres, was 
determined 4 hours post-treatment with the indicated doses of doxorubicin by western blotting. Proteins were extracted according to their 
subcellular localisation: F1, Cytosolic; F2, Membranes/organelles; F3, Nucleus; F4, Nucleus; F5, Cytoskeleton. 30 μg was loaded per lane. 
Coomassie staining (CM) confirmed that protein expression profiles from each fraction were distinct, 5 μg was loaded per lane.
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Figure 4: Gene expression analysis of canine glioma stem cells. (A) A three-dimensional representation of a principle component 
analysis of expression microarray data derived from untreated J3T adherent cells (0 Gy), irradiated adherent cells (5Gy), untreated spheres 
(0 Gy) and irradiated spheres (5 Gy). (B) Hierarchical clustering analysis of the expression data (cut off p-value of 0.005). Expression 
values are represented by colours: blue squares represent low-expressed genes, red squares represent high-expressed genes. (C) Biological 
process analysis of differentially expressed genes in J3T spheres compared to adherent cells (FDR = 0.005). (D) Validation of microarray 
with qRT-PCR.
Oncotarget8www.impactjournals.com/oncotarget
Inhibition of EGFR enhanced CSCs 
chemosensitivity
Surprisingly, gefitinib treatment alone had no 
significant effect on the cell viability of both canine 
and human CSCs (Figure 5B and 5C, respectively), 
but enhanced the proliferation of non-CSCs until doses 
exceeding 5 μM were used, whereby cell viability, of all cell 
populations, decreased in a dose dependent manner. This 
was the dose of gefitinib selected for further experiments.
To determine the effect of gefitinib on 
chemosensitivity, J3T adherent and sphere cells were pre-
incubated with gefitinib for 24 hours prior to treatment 
with increasing doses of doxorubicin for 48 hours, before 
cell viability was analysed. Combinational gefitinib 
and doxorubicin treatment had no effect on adherent 
non-CSCs (Figure 6A). However, in CSCs inhibition 
of EGFR enhanced the sensitivity of these cells to the 
cytotoxic effects of doxorubicin compared to control 
(Figure 6B). To substantiate these findings we analysed 
the clonogenic survival of doxorubicin treated cells with 
and without gefitinib. J3T CSCs are inherently more 
resistant to doxorubicin than non-CSCs in the absence 
of EGFR inhibition, however gefitinib enhanced the 
chemosensitivity of CSCs to a level comparable to non-
CSCs (Figure 6C). Interestingly, gefitinib alone reduced 
the colony forming ability of non-CSCs but had no 
effect on CSCs, until the cells were challenged with 
chemotherapy (Figure 6C). Similar results were obtained 
with human LN18 cells (Figure 6D).
Inhibition of EGFR sensitises glioma CSCs to 
radiation-induced cytotoxicity
As radiation treatment is the principal modality 
for treating glioma, we tested the combinational effect 
of EGFR inhibition and radiation on cell proliferation 
and clonogenic survival. Canine J3T (Figure 7A) and 
human LN18 (Figure 7B) adherent cells and spheres 
were treated with increasing doses of gefitinib (0 μM – 10 
μM) and increasing doses of ionising radiation (0 Gy – 5 
Gy). Gefitinib alone had no significant effect on the cell 
viability of either cell population (Figure 7A i) and 7B i)) 
until doses exceeding 5 μM were used. However, gefitinib 
in combination with ionizing radiation doses of 2.5 Gy 
(Figure 7A ii) and 7B ii)) and 5 Gy (Figure 7A iii) and 7B 
iii)), significantly increased the sensitivity of both CSCs 
and non-CSCs to radiation-induced cell death in a dose-
dependent manner. Consistent with previous results, CSCs 
were more resistant to the effects of EGFR inhibition 
than non-CSCs ((Figure 7A, 7B ii) and iii)). Clonogenic 
survival analysis is a longer-term assay that measures 
cell reproductive death after treatment, and here shows 
that non-CSCs were unaffected by pre-treatment with 
gefitinib prior to radiation at the indicated doses (Figure 
7C i) and 7D i)). Whereas inhibition of EGFR sensitised 
CSCs to the cytotoxic effects of increasing doses of 
ionising radiation (Figure 7C ii) and 7D ii)). These results 
indicate that combinational targeting of EGFR may be an 
effective method to overcome the intrinsic insensitivity to 
chemotherapy and radiation of CSCs.
DISCUSSION
GBM, the most aggressive and lethal primary 
brain tumour in both humans and dogs, portends a poor 
prognosis despite surgery, chemotherapy, and radiation 
[2, 4, 5]. GBM is characterized by a high degree of 
heterogeneity that reflects the presence of multiple 
subpopulations of cancer cells within the same tissue 
[29, 30]. Recurrence of tumour growth is attributed to the 
presence of treatment-resistant CSCs [8]. Future targeting 
of these CSCs is therefore essential in the treatment of this 
disease. CSCs have been isolated from primary cases of 
human [8, 10-13, 15] and canine GBM [14].
To date there are no bona fide cell surface markers 
available to distinguish non-CSCs from CSCs. CD133, 
which is expressed on hematopoietic [31] and neural 
stem cells [32], is widely used as a CSC marker in 
several tumours, including GBM, where cell sorting for 
CD133 expression can enrich for cells with tumourigenic 
potential [12, 13]. However, conflicting findings have 
called into question the utilization of this marker in brain 
tumours: there is a high variability of CD133 expression 
in GBM (from 1% to 60%); and GBM stem cells not 
expressing CD133, which are able to self-renew and 
regenerate tumours in the xenotransplantation assay, 
have been identified [33-35]. A recent study showed 
that neurospheres are composed of CD133-positive and 
CD133-negative cells, and although CD133-negative cells 
do not express CD133 on the plasma membrane they do 
show diffuse cytoplasmic staining [36]. Furthermore, the 
Table 1: Primer sequences for the amplification of RT-PCR products from canine cells
Gene Forward primer (5’-3’) Reverse primer (5’-3’) Product size
Oct4 CTCTGCAGCCAATCAACCACAA GGAGAGGGGGATGAGAAGTACAAT 237 bp
Nanog CTATAGAGGAGAGCACAGTGAAG GTTCGGATCTACTTTAGAGTGAGG 160 bp
STAT3 GTGGAGAAGGACATCAGCGGTAA AACTTGGTCTTCAGGTATGGGGC 250 bp
β-Actin CATGTTTGAGACCTTCAACACCC GCCATCTCTTGCTCGAAGTCCAG 229 bp
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subcellular localization of CD133 is plastic: shuttling 
between the cytoplasm and plasma membrane in response 
to cues from the microenvironment. Brescia et al (2013) 
concluded that CD133 is essential to the maintenance 
and tumourigenic potential of GBM CSCs [36]. Due to 
the ambiguity of CD133 as a universal marker of CSCs, 
we choose the neurosphere assay as a surrogate for in 
vitro study of GBM CSCs. In the present study, we have 
demonstrated that rare sub-populations of cancer cells 
exist in established canine and human glioma cell lines, 
which possess several distinct functional properties of 
CSCs, including expression of CD133, in vitro self-
renewal, increased invasiveness, preferential expression 
of embryonic stem cell markers and markers of EMT, and 
in vivo tumourigenic capacity.
We have also shown that CSCs are inherently 
resistant to chemotherapy, and due to this, doxorubicin 
treatment enhances the size of the CSC pool. Interestingly, 
CSCs lacked activation of the stress-activated transcription 
factor p53 and phosphorylation of γH2AX, an ATM target 
and a marker of DNA double strand breaks [26, 27]. 
This is consistent with human and mouse embryonic 
stem cells that lack the cell cycle checkpoint between 
G1 and S-phase and do not senesce after DNA damage, 
due to an inactive p53 pathway, which is to avoid severe 
depletion of the functional stem cell pool. Subsequent 
studies have highlighted that over-expression of p53 in 
ESCs leads to a suppression of self-renewal and induction 
of differentiation, and in the context of reprogramming, 
expression of wild-type p53 constrains iPSC generation 
in vitro [37-39]. Given that CSCs could arise from either 
the accumulation of genetic insults in normal stem cells 
or by dedifferentiation of existing differentiated cells, and 
that p53 is both a driver of differentiation and a barrier of 
dedifferentiation, our findings contribute to evidence that 
inactivation of p53 is a stem cell trait.
Global analysis of gene expression showed vast 
differences between J3T CSCs and non-CSCs, with 10,358 
significant differences. Comparisons of non-irradiated and 
irradiated CSCs revealed fewer significant differences (45), 
than that of non-CSCs (265), indicating that CSCs may 
indeed have a dampened down DNA damage response, 
reflected by reduced activity of ATM and p53. Data mining 
for biologically relevant targets highlighted that activators 
of the EGFR pathway, including EDNRA [40], CXCR7 
[41, 42], IGFBP2 [43] and EGR1 [44], are overexpressed 
in CSCs compared to non-CSCs. Even though EGFR 
itself was not overexpressed we showed that EGFR was 
constitutively active in CSCs and that this can be attenuated 
by treatment with the small molecule tyrosine kinase 
inhibitor, gefitinib. In humans EGFR is a potent driver of 
oncogenesis; over-expressed in a range of tumours; and is 
associated with worse overall survival [18, 45]. Similarly in 
dogs, there is significantly greater expression of EGFR in 
GBMs compared to other canine inter-cranial brain tumours 
that have been documented [46, 47]. In both neural stem 
cells and glioma CSCs activated EGFR signaling increases 
proliferation, survival, migration and blocks differentiation 
[7]. Here we show that inhibition of EGFR signaling alone 
had no effect on the viability of CSCs, however it does 
sensitise CSCs to the cytotoxic effects of chemotherapy 
and ionising radiation. In head and neck cancer resistance 
of tumour cells to radiotherapy has been shown to increase 
proportionally with EGFR expression, and it has been 
Table 3: The number of differentially expressed genes between the indicated cell populations of J3T spheres (SPH) 
and adherent (ADH) cells
p = 0.05 p = 0.005
J3T SPH V ADH (0 Gy) 15,193 10,358
J3T SPH V ADH (5 Gy) 13,634 8,841
J3T SPH (5 Gy) V SPH (0 Gy) 239 45
J3T ADH (5 Gy) V ADH (0 Gy) 1338 265
Table 2: Primer sequences for the amplification of qRT-PCR products from canine cell lines
Gene Forward primer (5’-3’) Reverse primer (5’-3’)
TNFAIP6 ACGGTTTTGTGGGAAGGTACT TTTGGAAACCTCCCGCTGTC
EDNRA GAATTACTTAGTTTCTTGCGTCTCA GGACTGGTAACAGCAACAGC
NGR1 CTGGTGATCGCTGCCAAAAC AGAGCTCCTCCGCTTCCATA
IL8 TGTTGCTCTCTTGGCAGCTT CGGATCTTGTTTCTCAGCCTTCTT
MRPS7 AGTGCAGGGAGAAGAAGCAC CAGCAGCTCGTGTGACAACT
GAPDH GGGAAGATGTGGCGTGAC GAAGGCCATGCCAGTGAG
Oncotarget10www.impactjournals.com/oncotarget
proposed that up-regulation of EGFR is a mechanism 
employed by cancer cells to circumvent the cytotoxic 
effects of radiotherapy [48, 49].
The effect of EGFR-targeted therapy has been 
extensively tested in preclinical human glioma models 
[50-52]. Small molecule tyrosine kinase inhibitors, 
including erlotinib and gefitinib, are well established in 
clinical practice for the treatment of lung carcinomas, yet 
showed a lack of activity in glioma [52]. An alternative 
approach is to use antibodies directed against EGFR, 
including cetuximab, nimotuzumab, and panitumumab, 
that prevent the binding of EGFR ligands to the receptor. 
Although these antibodies are clinically relevant in the 
treatment of advanced colorectal carcinoma [53, 54] and 
Figure 5: EGFR is constitutively active in CSCs. (A) J3T adherent and sphere cells were treated with 5 μM gefitinib and harvested 
over the indicated time course. Expression of EGFR, phosphorylation of EGFR at serine-1047 and tyrosine-1173, AKT, phosphorylation 
of AKT, and β-actin as a loading control. 20 μg was loaded per lane. (B, C) Comparison of the effect of increasing doses of gefitinib on 
proliferation of adherent and spheres of J3T (B) and LN18 cells (C). Cells were treated with increasing doses of gefitinib and cell viability 
was assayed 48 hours post treatment.
Oncotarget11www.impactjournals.com/oncotarget
metastatic breast cancer [55, 56], their implementation 
against intracranial neoplasms are challenging due to the 
presence of the blood-brain barrier, which may preclude 
the penetration of the antibody to all parts of the tumour. 
This has been mirrored in the treatment of glioma patients 
with pharmacological inhibitors of EGFR or blocking 
antibodies that fail to show signs of activity, indicating 
that inhibition of EGFR alone is insufficient [57-59]. 
It is interesting to speculate that termination of EGFR 
signaling may lead to the acquisition of compensatory 
additional genetic events, such as the expression of 
alternative tyrosine kinase receptors, and that disruption 
of converging signaling pathways may help overcome 
resistance to EGFR inhibitors.
Figure 6: Gefitinib decreases CSC resistance to doxorubicin. (A, B) J3T adherent (A) and spheres (B) were pre-treated with 
either a DMSO control or gefitinib (5 μM) for 24 hours, incubated with the indicated doses of doxorubicin and cell viability was assayed 
48 hours post-doxorubicin treatment. (C, D) Colony forming ability of adherent and spheres derived from J3T (C) and LN18 (D) cell lines 
was assayed after cells had been pre-treated with either a DMSO control or gefitinib (5 μM) for 24 hours prior to doxorubicin treatment 
(* p < 0.005, ** p < 0.001).
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Figure 7: Inhibition of EGFR sensitises glioma CSCs to radiation-induced cytotoxicity. J3T (A) and LN18 (B) adherent 
and spheres were treated with the indicated doses of gefitinib for 24 hours prior to treatment with either 0 Gy (i), 2.5 Gy (ii), or 5 Gy (iii), 
cell viability was assayed 48 hours post-irradiation treatment. Colony forming ability of adherent (i) and spheres (ii) derived from J3T (C) 
and LN18 (D) cell lines was assayed after cells had been pre-treated with either a DMSO control or gefitinib (5 μM) for 24 hours prior to 
treatment with indicated doses of irradiation (* p < 0.005).
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Table 4: Top biological functions of differentially expressed genes in J3T spheres compared to adherent cells  
(FDR = 0.005)
p-value Number of Molecules
Diseases and Disorders
Genetic Disorder 2.66E-20– 9.88E-04 2087
Cancer 1.29E-17 – 9.49E-04 1254
Gastrointestinal Disease 1.29E-17 – 8.67E-04 1215
Developmental Disorder 2.84E-12 – 1.10E-11 142
Infectious Disease 3.30E-12 – 4.57E-04 466
Molecular & Cellular Functions
Cell Cycle 1.40E-28 – 9.70E-04 544
Protein Synthesis 5.48E-20 – 5.91E-04 308
Cell Death 1.17E-19 – 9.57E-04 985
RNA Post-translational Modification 1.03E-17 – 7.49E-04 171
DNA Replication, Recombination and 
Repair 5.41E-17 – 9.25E-04 461
Physiological System Development & 
Function
Organismal Survival 1.56E-09 – 4.94E-09 328
Organismal Development 9.61E-07 – 9.12E-04 267
Connective Tissue Development and 
Function 1.47E-05 – 5.88E-04 162
Tissue Development 1.47E-05 – 7.01E-04 151
Tumour Morphology 9.20E-05 – 9.20E-05 82
Table 5: Top ten upregulated genes in J3T spheres compared to adherent cells (FDR = 0.005)
Gene Symbol Gene Name Accession Number Gene Ontology Fold Change
EDNRA endothelin receptor type A P25101 G-protein coupled receptor 78.64
CXCR7 chemokine (C-X-C motif) receptor 7 P25106
G-protein coupled 
receptor 72.45
TNFAIP6 Tumor Necrosis Factor, Alpha-Induced Protein 6 P98066
extracellular matrix 
stability and cell 
migration
44.29
COL3A1 collagen, type III, alpha 1 P02461 Component of connective tissues 37.14
FAP fibroblast activation protein, alpha Q12884 Wound healing 28.68
LUM lumican P51884 Extra cellular matrix structural constituent 27.57
IGFBP2 insulin-like growth factor binding protein 2, 36kDa P18065
Inhibition of IGF-
mediated growth and 
development
27.13
LMCD1 LIM and cysteine-rich domains 1 Q9NZU5
Transcription 
corepressor activity 21.43
CDO1 cysteine dioxygenase, type I Q16878
Cysteine dioxygenase 
activity 20.65
EGR1 early growth response 1 P18146 Transcriptional regulator 20.57
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Several studies have previously suggested a 
sensitizing effect of inhibition of EGFR to radiation 
[23, 60-63]. Clinical trials to explore the combination of 
radiation therapy with inhibition of EGFR in patients with 
newly diagnosed glioblastoma failed to show an increase 
in survival compared to historical controls [64, 65]. 
Patients were not selected for these trials on the basis of 
high expression of EGFR. However gene amplification 
or expression of wild-type EGFR or expression of a 
mutant form called EGFR variant III (EGFRvIII) is 
found in approximately 40-50% of all human gliomas 
[16]. EGFRvIII arises from an in-frame deletion of exons 
2-7 from the extracellular domain, leading to a loss of 
ligand binding potential, constitutive activation of the 
receptor and resistance to gefitinib [66]. Rather than global 
overexpression of EGFR throughout the tumour, our data in 
the J3T cell line shows that a minority population of CSCs 
do not over-express of EGFR but do have constitutive 
activation of EGFR compared to the bulk of the tumour 
cells, that can be attenuated by treatment with gefitinib. 
Successful targeting of CSCs is of paramount importance 
as these cells have been suggested to be responsible for the 
treatment resistance and recapitulating tumour growth in 
GBM patients. Radiotherapy is currently the key treatment 
modality for GBM, but efficacy is limited by radio-
resistance that may be mediated by CSCs. We have shown 
that CSCs were significantly more resistant to chemotherapy 
and radiation than non-CSCs, and that inhibition of EGFR, 
by gefitinib, can sensitise both human and canine glioma 
CSCs to the cytotoxic effects of doxorubicin and radiation. 
Our data indicates that inhibition of EGFR has a role as part 
of a multimodal therapy in overcoming resistance of CSCs 
to conventional therapies.
MATERIALS AND METHODS
Cell culture and sphere formation
The tumour cell lines used in this study were the 
canine glioma cell line J3T [67, 68], and human glioma cell 
line LN18 [69], both were obtained commercially (ATCC, 
Middlesex, UK). J3T cells were grown in Dulbecco’s 
modified Eagle’s medium (DMEM) (Invitrogen, Paisley, 
UK) supplemented with 10 % fetal bovine serum and 100 
μg/ml streptomycin (Invitrogen, Paisley, UK). LN18 were 
grown in DMEM (Invitrogen, Paisley, UK) supplemented 
with 10 % fetal bovine serum and 100 μg/ml streptomycin.
For anchorage-independent culture, cells were 
plated as single cells in ultra-low attachment 6-well plates 
(Corning, CA, USA) at low cell density (1.5 x 104 cells/
ml). Cells were grown in serum-free conditional medium, 
which contained William’s E Medium with GlutaMAX 
supplemented with putrescine (100 μM), sodium selenite 
(30 nM), transferrin (25 μg/ml), insulin (20 μg/ml) (Sigma 
Biochemicals, Dorset, UK), human recombinant bFGF 
(10 ng/ml) (Peprotech, NJ, USA). Additional bFGF (100 
μg/ml) was added to the media every other day. All cell 
cultures were maintained at 37 oC in a humidified CO2 
incubator.
Magnetic cell sorting
Cells were labelled with CD133 microbeads and 
sorted using the Miltenyi Biotec CD133 cell isolation 
kit according to the manufacturer’s protocol (Miltenyi 
Biotec, Surrey, UK). Briefly, cells were resuspended in 
300 μl PBS solution (pH 7.2, 0.5% BSA, 2 mM EDTA) 
per 108 cells. Then blocking reagent FcR (100 μl/108 cells; 
Miltenyi Biotec, Surrey, UK) and CD133 microbeads (100 
μl/108 cells) were added and mixed at 4 oC for 30 minutes 
with rotation. Cells were washed in 20x volume with 
PBS solution. The pellet was resuspended in 500 μl PBS 
solution and added to a pre-washed magnetic separation 
(LS) column on the magnetic holder. The column was 
washed four times and the cells were collected as the 
negative fraction. The column was removed from the 
magnetic holder and the positive fraction was collected.
Sphere forming efficiency
The sphere forming ability of CD133 sorted cells was 
determined by resuspending cells in serum-free conditional 
medium at a density of 20,000; 10,000; 5,000; or 2,000 
cells/well in 6–well low adherence plates (Corning, CA, 
USA). All experiments were conducted in triplicate. Plates 
were maintained at 37 °C in humidified CO2 incubator 
and were fed every other day. After 10 days colonies were 
counted under the microscope in 10 fields per well.
Cytotoxic drug or radiation treatment
Cells were grown to 70% confluency before treating 
with indicated drug or stress. Cells were irradiated in 
culture medium using a Faxitron® cabinet X-ray system, 
43855D (Faxitron X-ray Corporation, Lincolnshire, 
IL, USA), at a central dose rate of 2 Gy/min. Cells 
were irradiated at the stated doses and harvested at the 
stated time points. Cells were treated with doxorubicin 
(Pharmacia/Pfizer, Sandwich, UK) or gefitinib (Tocris 
Bioscience, Bristol, UK), within the indicated dose range. 
All drugs were dissolved in dimethyl sulfoxide, and 
diluted in media immediately before use. Vehicle controls 
were included in all experiments.
Analysis of cytotoxicity
Cells were trypsinised into single cells and seeded in 
quadruplet in opaque 96-well plates (Corning, CA, USA) 
at 500 cells/well. Serial dilutions of doxorubicin, gefitinib, 
or ionising radiation were added to the appropriate cells 
the following day or as indicated. Dose-response curves 
were generated 48 hours after exposure. Cytotoxicity 
was measured using the CellTiterGlo® Luminescent 
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Cell Viability Assay (Promega, Madison, USA), which 
quantifies the number of viable cells in culture based on 
quantification of ATP present. Luminescence was recorded 
by luminometer (Viktor3, PerkinElmer, Massachusetts, 
USA). Data was averaged and normalized against the 
average signal of untreated/vehicle control treated samples.
Colony formation assay
Cells were trypsinised into single cells and seeded 
at 500 cells/10 cm plate. The cells were treated with the 
indicated dose of doxorubicin or ionising radiation whilst 
in suspension. Plates were incubated at 37 oC in humidified 
CO2 incubator until colonies were visible. Growth media 
was changed once a week. The colonies were fixed by 
incubating with ice-cold methanol for 5 minutes at room 
temperature. Colonies were stained with Giemsa stain 
(Invitrogen, Paisley, UK) according to the manufacturer’s 
instruction. The total number of colonies was counted.
Invasion assay
The cell invasion ability of isolated cells was 
determined using the QCM™ collagen-based cell 
invasion assay kit (Millipore, MA, USA) according to the 
manufacturer’s instructions. Cells were seeded into the 
upper inserts at 1 x 105 cells/insert in William’s E Medium 
with GlutaMAX. Outer wells were filled with William’s E 
Medium with GlutaMAX. Cells were incubated at 37oC 
with 5% CO2 for 48 hours. The non-invading cells were 
removed. Cells that migrated through the gel insert to the 
lower surface were stained and quantified by colorimetric 
measurement at 560 nm.
Chick embryo chorioallantoic membrane assay
Fertilised ISABrown layer strain chicken eggs (Roslin 
Institute Poultry Unit) were incubated in a humidified rotary 
incubator at 37 oC. On day 3, a small window was opened in 
the shell after removal of 2-3 ml of albumin, to detach the 
CAM from the shell and to disclose the underlying CAM 
vessels. The window was sealed with tape and incubation 
was continued until day 7. On day 7, single cell suspensions 
of adherent cells and mammospheres were labelled with 
PKH26 (Sigma-Aldrich, MO, USA), a red fluorescent 
live cell membrane dye, according to manufacturer’s 
instructions. Viable 105 (n=4) cells were suspended in a 
1:1 mixture of serum-free media:matrigel, and 25 μL was 
inoculated directly onto the CAM. The embryos were 
resealed and incubated without turning. At day 10, tumour 
growth and location were determined.
Protein detection
Cells were lysed in urea lysis buffer (7 M urea, 
0.1 M DTT, 0.05 % Triton X-100, 25 mM NaCl, 20 mM 
Hepes pH 7.5). Equal amounts of protein were separated 
by SDS polyacrylamide gel electrophoresis (SDS PAGE), 
transferred to Hybond-C nitrocellulose membrane 
(Amersham Pharmacia Biotech, Buckinghamshire, UK). 
Non-specific antibody binding was blocked by incubating 
membranes in 5 % milk/ 1 % β-glycerophosphate/ PBST 
for 1 hr at room temperature. β-glycerophosphate is a 
serine/threonine phosphatase inhibitor critical for the 
retention of phosphorylation modifications. Membranes 
were probed with appropriate primary antibody for 3 hr 
at room temperature or overnight at 4 oC. Membranes 
were washed once in PBST. Specific antibody binding 
was detected by incubating membranes for 1 hr at room 
temperature with a secondary horseradish peroxidase 
(HRP) conjugated antibody diluted 1:1000 in 5 % milk/ 
1% β-glycerophosphate/ PBST. Following three 15 min 
washes in PBST, membranes were treated with ECL 
chemiluminescent detection system (2 ml /blot, 1:1 ratio 
ECL I : ECL II) and protein bands were visualized by 
exposure to X-ray film (Kodak). Antibodies against Primary 
antibodies were β-actin, γ-H2AX, EGFR and phosphor-
EGFR (Ser1047) (Abcam), β-catenin, E-cadherin and 
fibronectin (BD Biosciences), AKT, phospho-AKT (Ser473) 
and phospho-p53 (Ser15) (Cell Signaling), MDM2 (4B2) 
and p53 (DO1) (Moravain Biotechnology), phospho-
EGFR (Tyr 1173) (SantaCruz Biotechnology). Secondary 
antibodies were HRP-conjugated rabbit anti-mouse IgG and 
swine anti-rabbit IgG (DakoCytomation).
Subcellular proteome extraction
The Subcellular Proteome Fractionation Kit (Thermo 
Scientific) was used to extract proteins from mammalian 
cells according to their subcellular localisation. All fractions 
were stored at -70 °C and analysed by immunoblotting (see 
above).
RNA extraction and reverse transcription PCR 
analysis
Total cellular RNA was extracted using RNeasy® kit 
(Qiagen, CA, USA) and RNA quality was determined by 
A260 measurement. Semi-quantitative RT-PCR analysis of 
mRNA expression of stem cell specific genes including 
Oct4, Nanog and STAT3 was performed using HotStar 
Taq polymerase (Qiagen, CA, USA) and specific primers 
(Table 4.)
Real-time quantitative PCR
Total RNA was reverse transcribed using the 
omniscript RT Kit (Qiagen, CA, USA) according to 
the manufacturer’s instruction. Real-time PCR was 
performed on 50 ng of amplified RNA using a Stratagene 
Mx3000p qPCR system (Aligent, CA, USA), using 
the Platinum® SYBR® Green qPCR SuperMix-UDG 
according to manufacturer’s instruction (Invitrogen, 
CA, USA). Relative gene expression levels of TNFAIP6, 
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EDNRA, NGR1 and IL8 were obtained by normalization 
to the expression levels of housekeeping genes (MRPS7, 
GAPDH). Primer sequences are shown in Table 5.
Gene expression profiling using cDNA 
microarrays
RNA was isolated from frozen cell pellets of untreated 
(0 Gy) and irradiated (5 Gy) J3T spheres and adherent cells, 
with TriReagent (Sigma-Aldrich, MO, USA) according to 
manufacturer’s instruction. Four independent replicates were 
used for each sample. Total RNA quality was determined by 
Bioanalyser (Agilent, CA, USA) before further manipulation. 
Complementary RNA preparation and hybridization were 
performed by ARK-Genomics (Edinburgh, UK) using 
Affymetrix GeneChip® Canine Genome 2.0 Array (42,800 
probe sets). Basic data analysis was performed using the 
Partek Genomics Suite (Partek Inc, MO, USA). Pathway 
analysis was performed using Ingenuity Pathway Analysis 
(IPA, Ingenuity systems; https://www.analysis.ingenuity.
com). Genes from the dataset that met the log ratio cut-off 
of 1.5 were considered for the analysis. To identify the most 
relevant canonical pathways, we selected those that were 
statistically significant with a p value < 0.005. All microarray 
data has been submitted to the NCBI Gene Expression 
Omnibus database.
Statistical analysis
Data were expressed as a mean ±SD. Statistical 
analysis was performed with Minitab® statistical software 
(PA, USA) using analysis of variance and student’s t test 
or mann-whitney test. The criterion for significance was p 
< 0.05 for all comparisons.
CONCLUSIONS
In summary, our findings demonstrate that CSCs 
exist in the canine glioma cell line, J3T and the human 
glioma cell line, LN18. These cells are more invasive, 
more tumourigenic and more resistant to chemotherapy 
and irradiation compared with non-CSC glioma cells. 
Global gene expression analysis has demonstrated that the 
gene expression profiles of these subpopulations of glioma 
cells significantly differ, and we have consequently shown 
differences in the p53 and EGFR signaling pathways. 
Activators of the EGFR pathway were over-expressed in 
CSCs compared to non-CSCs, and we subsequently showed 
that CSCs were more sensitive to the effect of gefitinib, 
which enhanced radiosensitivity and increased cytotoxicity.
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